Increased deaths shadow AstraZeneca, Daiichi’s Enhertu first-line lung cancer data

A preliminary 15% higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ADC Enhertu as a first-line treatment for patients with HER2-mutant non-small cell lung cancer.